Clinical Trials Browser

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

220 enrolled

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

19 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

10 enrolled

Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

208 enrolled

Head & Neck

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

180 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

Clinical Trials

N01-A-PICIT-GI

N01-A-PICIT-GT

I-SPY

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

TAGVEN

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC